# A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE

> **NCT04656613** · PHASE3 · UNKNOWN · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 1000 (estimated)

## Conditions studied

- Covid19
- SARS-CoV Infection

## Interventions

- **BIOLOGICAL:** Gam-COVID-Vac
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04656613
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12
- **Primary completion:** 2021-08
- **Final completion:** 2021-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2020-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656613, "A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04656613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*